Ignite Creation Date:
2024-05-06 @ 6:18 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05613478
Status:
RECRUITING
Last Update Posted:
2022-11-14
First Post:
2022-11-06
Brief Title:
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-06
First Submit QC Date:
November 6 2022
Study First Post Date:
2022-11-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-06
Last Update Post Date:
2022-11-14
Last Update Post Date Type:
ACTUAL